Y-mAbs Therapeutics (NASDAQ:YMAB) Given "Buy" Rating at HC Wainwright

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $22.00 target price on the stock. HC Wainwright's price target suggests a potential upside of 238.46% from the stock's current price.

YMAB has been the topic of a number of other reports. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a "buy" rating and a $17.00 target price on the stock. Oppenheimer initiated coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an "outperform" rating and a $23.00 target price for the company. Finally, Wedbush reissued an "outperform" rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Friday. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Y-mAbs Therapeutics presently has a consensus rating of "Buy" and an average price target of $20.89.

Y-mAbs Therapeutics Trading Down 5.7 %

NASDAQ YMAB traded down $0.39 on Monday, hitting $6.50. 675,923 shares of the stock traded hands, compared to its average volume of 399,589. The stock has a 50-day moving average of $10.32 and a 200 day moving average of $12.13. Y-mAbs Therapeutics has a twelve month low of $6.24 and a twelve month high of $20.90. The company has a market capitalization of $291.13 million, a P/E ratio of -12.04 and a beta of 0.69.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $18.46 million for the quarter, compared to the consensus estimate of $23.38 million. During the same quarter last year, the firm posted ($0.18) earnings per share. As a group, equities research analysts expect that Y-mAbs Therapeutics will post -0.66 earnings per share for the current year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several hedge funds have recently modified their holdings of YMAB. Caligan Partners LP boosted its holdings in Y-mAbs Therapeutics by 105.3% in the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company's stock valued at $15,718,000 after purchasing an additional 613,175 shares during the period. State Street Corp grew its position in Y-mAbs Therapeutics by 50.4% during the third quarter. State Street Corp now owns 1,209,781 shares of the company's stock worth $15,909,000 after buying an additional 405,169 shares in the last quarter. Squarepoint Ops LLC increased its stake in Y-mAbs Therapeutics by 143.4% during the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company's stock valued at $1,527,000 after acquiring an additional 74,452 shares during the period. Millennium Management LLC lifted its position in shares of Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company's stock worth $4,225,000 after acquiring an additional 67,233 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Y-mAbs Therapeutics by 15.7% during the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company's stock valued at $5,853,000 after purchasing an additional 65,732 shares during the period. 70.85% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.